Search

Your search keyword '"Purandare, Nilendu C."' showing total 380 results
Start Over Author "Purandare, Nilendu C."
380 results on '"Purandare, Nilendu C."'

1. FET PET to differentiate between post-treatment changes and recurrence in high-grade gliomas: a single center multidisciplinary clinic controlled study

Author

Puranik, Ameya D., Dev, Indraja D., Rangarajan, Venkatesh, Jain, Yash, Patra, Sukriti, Purandare, Nilendu C., Sahu, Arpita, Choudhary, Amitkumar, Bhattacharya, Kajari, Gupta, Tejpal, Chatterjee, Abhishek, Dasgupta, Archya, Moiyadi, Aliasgar, Shetty, Prakash, Singh, Vikas, Sridhar, Epari, Sahay, Ayushi, Shah, Aekta, Menon, Nandini, Ghosh, Suchismita, Choudhury, Sayak, Shah, Sneha, Agrawal, Archi, Lakshminarayanan, N., Kumar, Amit, and Gopalakrishna, Arjun

Published
2024
Full Text
View/download PDF

2. Nuclear Medicine in Oncology

Author

Rangarajan, Venkatesh, Purandare, Nilendu C., Basu, Sandip, Badwe, Rajendra A., editor, Gupta, Sudeep, editor, Shrikhande, Shailesh V., editor, and Laskar, Siddhartha, editor

Published
2024
Full Text
View/download PDF

5. Tata Memorial Centre Evidence Based Use of Nuclear medicine diagnostic and treatment modalities in cancer

Author

Puranik, Ameya D., Choudhury, Sayak, Ghosh, Suchismita, Dev, Indraja D., Ramchandani, Varun, Uppal, Abhishek, Bhosale, Vikrant, Palsapure, Abhishek, Rungta, Rachita, Pandey, Rakesh, Khatri, Shweta, George, Gemson, Satamwar, Yogesh, Maske, Rahul, Agrawal, Archi, Shah, Sneha, Purandare, Nilendu C., and Rangarajan, Venkatesh

Subjects
PET imaging, Cancer -- Care and treatment -- Diagnosis -- Development and progression -- Drug therapy, Evidence-based medicine, Health, National Comprehensive Cancer Network
Abstract

PET/CT and radioisotope therapy are diagnostic and therapeutic arms of Nuclear Medicine, respectively. With the emergence of better technology, PET/CT has become an accessible modality. Diagnostic tracers exploring disease-specific targets has led the clinicians to look beyond FDG PET. Moreover, with the emergence of theranostic pairs of radiopharmaceuticals, radioisotope therapy is gradually making it's way into treatment algorithm of common cancers in India. We therefore would like to discuss in detail the updates in PET/CT imaging and radionuclide therapy and generate a consensus-driven evidence based document which would guide the practitioners of Oncology. Keywords: Oncology, PET/CT, radioisotope, radioligand, theranostics, Author(s): Ameya D. Puranik [1]; Sayak Choudhury [1]; Suchismita Ghosh [1]; Indraja D. Dev [1]; Varun Ramchandani [1]; Abhishek Uppal [1]; Vikrant Bhosale [1]; Abhishek Palsapure [1]; Rachita Rungta [1]; [...]

Published
2024
Full Text
View/download PDF

7. An Audit of Systemic Therapy in Medullary Carcinoma Thyroid

Author

Kanteti, Aditya Pavan Kumar, Abraham, George, Patil, Vijay M., Menon, Nandini, Mandal, Tanmoy, Jacob, Sobin V., Garg, Keshav, Sekar, Anbarasan, Sarma, Rup Jyoti, Mekala, Laxma Reddy, Nakti, Dipti, Mittal, Neha, Bal, Munita, Rane, Swapnil, Purandare, Nilendu C., Mahajan, Abhishek, Sable, Nilesh, Kumar, Suman, Noronha, Vanita, and Prabhash, Kumar

Published
2022
Full Text
View/download PDF

8. Radiology of Non-Hodgkin Lymphoma

Author

Ankathi, Suman Kumar, Purandare, Nilendu C., Bomanji, Jamshed B., Series Editor, Gnanasegaran, Gopinath, Series Editor, Fanti, Stefano, Series Editor, Macapinlac, Homer A., Series Editor, Agrawal, Archi, editor, Rangarajan, Venkatesh, editor, and Puranik, Ameya D., editor

Published
2021
Full Text
View/download PDF

14. Rare Cases of Extracranial Metastases from High-grade Glioma Detected on FET PET-CT with Histopathological Confirmation.

Author

Dev, Indraja Devidas, Sahay, Ayushi, Puranik, Ameya D., Purandare, Nilendu C., Agrawal, Archi, Shah, Sneha, Choudhury, Sayak, Ghosh, Suchismita, and Rangarajan, Venkatesh

Subjects
POSITRON emission tomography computed tomography, OVERALL survival, SPINAL cord, GLIOMAS, BIOLOGY
Abstract

Extracranial metastasis from high-grade glial tumors is an extremely rare condition with its reported incidence being <1%. The most common sites reported in the literature are leptomeninges and spinal cord, followed by the liver, lung, and skeletal system. Its low incidence is thought to be related to the intrinsic aggressive biology of the tumor, thus reducing median overall survival in patients. As there is lack of knowledge about the mechanism of extracranial spread of glioma cells, its diagnosis and management remain a major challenge. We report two cases of extracranial metastases from glial tumors to cervical nodes and postoperative site involving preauricular region detected on F18 Fluoro ethyl tyrosine (FET) positron emission tomography-computed tomography and later on confirmed with histopathology Fluoro ethyl tyrosine. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Lung Cancer Pictorial Atlas

Author

Purandare, Nilendu C., Agrawal, Archi, Shah, Sneha, Rangarajan, Venkatesh, Bomanji, Jamshed B., Series editor, Gnanasegaran, Gopinath, Series editor, Fanti, Stefano, Series editor, Macapinlac, Homer A., Series editor, Agrawal, Archi, editor, and Rangarajan, Venkatesh, editor

Published
2018
Full Text
View/download PDF

19. PRRT with Lu-177 DOTATATE in Treatment-Refractory Progressive Meningioma: Initial Experience from a Tertiary-Care Neuro-Oncology Center.

Author

Puranik, Ameya D., Dev, Indraja D., Rangarajan, Venkatesh, Kulkarni, Suyash, Shetty, Nitin, Gala, Kunal, Sahu, Arpita, Bhattacharya, Kajari, Dasgupta, Archya, Chatterjee, Abhishek, Gupta, Tejpal, Sridhar, Epari, Sahay, Ayushi, Shetty, Prakash, Singh, Vikas, Moiyadi, Aliasgar, Menon, Nandini, Purandare, Nilendu C., Agrawal, Archi, and Shah, Sneha

Subjects
PEPTIDE receptors, ABSORBED dose, RF values (Chromatography), MENINGIOMA, DISEASE progression
Abstract

Purpose: Refractory and/or recurrent meningiomas have poor outcomes, and the treatment options are limited. Peptide receptor radionuclide therapy (PRRT) has been used in this setting with promising results. We have documented our experience of using intravenous (IV) and intra-arterial (IA) approaches of Lu-177 DOTATATE PRRT. Methods: Eight patients with relapsed/refractory high-grade meningioma received PRRT with Lu-177 DOTATATE by IV and an IA route. At least 2 cycles were administered. Time to progression was calculated from the first PRRT session to progression. The response was assessed on MRI using RANO criteria, and visual analysis of uptake was done on Ga-68 DOTANOC PET/CT. Post-therapy dosimetry calculations for estimating the absorbed dose were performed. Results: Median time to progression was 8.9 months. One patient showed disease progression, whereas seven patients showed stable disease at 4 weeks following 2 cycles of PRRT. Dosimetric analysis showed higher dose and retention time by IA approach. No significant peri-procedural or PRRT associated toxicity was seen. Conclusion: PRRT is a safe and effective therapeutic option for relapsed/refractory meningioma. The IA approach yields better dose delivery and should be routinely practised. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Intra‑arterial PRRT with Lu‑177 DOTATATE in Liver‑dominant Metastatic Neuroendocrine Tumors: Early Assessment of Efficacy and Toxicity.

Author

Puranik, Ameya D., Rangarajan, Venkatesh, Shetty, Nitin Sudhakar, Gala, Kunal, Kulkarni, Suyash, Mohite, Ashish, Marotkar, Mandar, Gawale, Yogesh, Dev, Indraja D., Shrikhande, Shailesh V., Chaudhari, Vikram, Bhandare, Manish, Agrawal, Archi, Shah, Sneha, Purandare, Nilendu C., Ghosh, Suchismita, and Choudhury, Sayak

Subjects
NEUROENDOCRINE tumors, POSITRON emission tomography, SOMATOSTATIN receptors, PEPTIDE receptors, GLOMERULAR filtration rate
Abstract

Purpose: We proposed to administer Lu‑177‑DOTATATE in intra‑arterial (IA) mode for higher first‑pass localization to somatostatin receptors, higher residence time in liver metastases, and more radiation to tumor. This study aimed at assessing early hematological, renal and hepatotoxicity; and objective response to IA peptide receptor radionuclide therapy (PRRT). Materials and Methods: Fourteen patients (4 females and 10 males) were prospectively assessed. 5/14 patients underwent 2 cycles, whereas 3/14 underwent 3 cycles, and 6/14 received 1 cycle of IA PRRT. 200 mCi of Lu‑177‑DOTATATE was administered in 15–20 min by IA route under angiographic guidance. Patients were asked to follow‑up at 4 and 8 weeks with hematological, liver, and renal functional parameters, and Ga‑68 DOTATATE positron emission tomography/computed tomography (PET/CT) after 8 weeks. Response was assessed using RECIST 1.1 and EORTC PET criteria. Results: Safety: 2/14 patients had high total and direct bilirubin, which reverted to normal after IA PRRT. Three patients had low albumin, which improved after 1 cycle. Nine patients showed no worsening of liver function. Two patients showed Grade 1 hematotoxicity which reverted to normal. Five patients showed high creatinine, but preserved glomerular filtration rate and EC clearance. On follow‑up at 8 weeks, serum creatinine reverted to normal. Efficacy: In five patients who underwent 2 cycles of IA PRRT, 3 showed partial response (PR) on RECIST 1.1 and partial metabolic response (PMR) on EORTC criteria, whereas 2 showed stable disease (SD). In patients who underwent 3 cycles, 1 showed SD, whereas other patient showed PMR on DOTANOC PET/ CT, with PR in size. Among the remaining seven patients, 5 showed PMR, whereas the other 2 showed SD. Thus 9/14 patients showed PR, whereas 5 showed SD on metabolic and size criteria. Conclusions: IA PRRT is a safe and efficacious approach for the treatment of liver dominant metastatic neuroendocrine tumors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Radiomics: a quantitative imaging biomarker in precision oncology

Author

Jha, Ashish Kumar, Mithun, Sneha, Purandare, Nilendu C, Kumar, Rakesh, Rangarajan, Venkatesh, Wee, Leonard, Dekker, Andre, Jha, Ashish Kumar, Mithun, Sneha, Purandare, Nilendu C, Kumar, Rakesh, Rangarajan, Venkatesh, Wee, Leonard, and Dekker, Andre

Abstract

Cancer treatment is heading towards precision medicine driven by genetic and biochemical markers. Various genetic and biochemical markers are utilized to render personalized treatment in cancer. In the last decade, noninvasive imaging biomarkers have also been developed to assist personalized decision support systems in oncology. The imaging biomarkers i.e., radiomics is being researched to develop specific digital phenotype of tumor in cancer. Radiomics is a process to extract high throughput data from medical images by using advanced mathematical and statistical algorithms. The radiomics process involves various steps i.e., image generation, segmentation of region of interest (e.g. a tumor), image preprocessing, radiomic feature extraction, feature analysis and selection and finally prediction model development. Radiomics process explores the heterogeneity, irregularity and size parameters of the tumor to calculate thousands of advanced features. Our study investigates the role of radiomics in precision oncology. Radiomics research has witnessed a rapid growth in the last decade with several studies published that show the potential of radiomics in diagnosis and treatment outcome prediction in oncology. Several radiomics based prediction models have been developed and reported in the literature to predict various prediction endpoints i.e., overall survival, progression-free survival and recurrence in various cancer i.e., brain tumor, head and neck cancer, lung cancer and several other cancer types. Radiomics based digital phenotypes have shown promising results in diagnosis and treatment outcome prediction in oncology. In the coming years, radiomics is going to play a significant role in precision oncology.

Published
2022

38. Prognostic value of lung shunt fraction in hepatocellular carcinoma and unresectable liver dominant metastatic colorectal cancer undergoing transarterial radioembolisation

Author

Gosavi, Atul, primary, Puranik, Ameya D., additional, Shah, Sneha, additional, Agrawal, Archi, additional, Purandare, Nilendu C., additional, Shetty, Nitin, additional, Gala, Kunal, additional, Kulkarni, Suyash, additional, Patkar, Shraddha, additional, Goel, Mahesh, additional, Shrikhande, Shailesh, additional, Ramaswamy, Anant, additional, Ostwal, Vikas, additional, and Rangarajan, Venkatesh, additional

Published
2021
Full Text
View/download PDF

39. An Audit of Systemic Therapy in Medullary Carcinoma Thyroid

Author

Kanteti, Aditya Pavan Kumar, primary, Abraham, George, additional, Patil, Vijay M., additional, Menon, Nandini, additional, Mandal, Tanmoy, additional, Jacob, Sobin V., additional, Garg, Keshav, additional, Sekar, Anbarasan, additional, Sarma, Rup Jyoti, additional, Mekala, Laxma Reddy, additional, Nakti, Dipti, additional, Mittal, Neha, additional, Bal, Munita, additional, Rane, Swapnil, additional, Purandare, Nilendu C., additional, Mahajan, Abhishek, additional, Sable, Nilesh, additional, Kumar, Suman, additional, Noronha, Vanita, additional, and Prabhash, Kumar, additional

Published
2021
Full Text
View/download PDF

40. Brain FET PET tumor‐to‐white mater ratio to differentiate recurrence from post‐treatment changes in high‐grade gliomas

Author

Puranik, Ameya D., primary, Rangarajan, Venkatesh, additional, Dev, Indraja D., additional, Jain, Yash, additional, Purandare, Nilendu C., additional, Sahu, Arpita, additional, Choudhary, Amitkumar, additional, Gupta, Tejpal, additional, Chatterjee, Abhishek, additional, Moiyadi, Aliasgar, additional, Shetty, Prakash, additional, Sridhar, Epari, additional, Sahay, Ayushi, additional, Patil, Vijay M., additional, Shah, Sneha, additional, and Agrawal, Archi, additional

Published
2021
Full Text
View/download PDF

46. Improving accuracy of 18F-fluorodeoxyglucose PET computed tomography to diagnose nodal involvement in non-small cell lung cancer: utility of using various predictive models

Author

Mathew, Boon, primary, Purandare, Nilendu C., additional, Pramesh, C S, additional, Karimundackal, George, additional, Jiwnani, Sabita, additional, Agrawal, Archi, additional, Shah, Sneha, additional, Puranik, Ameya, additional, Kumar, Rajiv, additional, Prakash Agarwal, Jai, additional, Prabhash, Kumar, additional, Tandon, Sandeep, additional, and Rangarajan, Venkatesh, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results